For these targets, the human glioma LN-18 cell line was used to evaluate downregulation activity due to its high expression level of IDO-1, PDL1, and TGF-β2 with or without induction by IFNγ (Figure S3). The gene discussed is TGFB2; the disease is central nervous system cancer.